Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization

Journal of Cardiovascular Medicine

Volumn 10, Issue 2, 2009, Pages 135-142

  Gunaydin, Serdar ^a   Farsak, Bora ^b   McCusker, Kevin ^c   Vijay, Venkataramana ^d   Sari, Tamer ^e   Onur, M Ali ^b   Gurpinar, Aylin ^b   Zorlutuna, Yaman ^e  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e BAYINDIR HOSPITAL   (Turkey)

Author keywords

Biocompatible; Cardiopulmonary bypass; Coated materials; Coronary artery bypass; Hyaluronan; Oxygenator

Indexed keywords

ANTITHROMBIN; BIOMATERIAL; FRESH FROZEN PLASMA; HEPARIN; HYALURONIC ACID; INTERLEUKIN 2; PROTAMINE; PROTAMINE SULFATE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TROPONIN T; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; COMPLEMENT COMPONENT C3A; HEPARIN ANTAGONIST; IL2 PROTEIN, HUMAN; PEPTIDE HYDROLASE;

ADULT; ANESTHESIA INDUCTION; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY SINUS; CORONARY SINUS BLOOD FLOW; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; EXTRACORPOREAL CIRCULATION; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HEPARINIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REOPERATION; SYSTEMIC THERAPY; THROMBOCYTE COUNT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EQUIPMENT DESIGN; FEASIBILITY STUDY; INFLAMMATION; INSTRUMENTATION; MATERIALS TESTING; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTITHROMBIN III; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT C3A; CORONARY ARTERY BYPASS; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; HEPARIN; HEPARIN ANTAGONISTS; HUMANS; HYALURONIC ACID; INFLAMMATION; INTERLEUKIN-2; MALE; MATERIALS TESTING; MIDDLE AGED; PEPTIDE HYDROLASES; PLATELET COUNT; PROSPECTIVE STUDIES; PROTAMINES; REOPERATION; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

EID: 65549128732     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32831eef9d     Document Type: Article

References (19)

1. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75:S715-S720.
2. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994; 31:261-269.
3. Ovrum E, Tangen G, Oystese R, Ringdal MAL, Istad R. Comparison of two heparin coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg 2001; 121:324-330. (Pubitemid 32150922)
4. Videm V, Mollnes TE, Fosse E, Mohr B, Bergh K, Hagve TA, et al. Heparin coated cardiopulmonary bypass equipment: biocompatibility markers and development of complications in a high risk population. J Thorac Cardiovasc Surg 1999; 117:794-802. (Pubitemid 29163085)
5. Ovrum E, Tangen G, Oystese R, Ringdal ML, Istad R. Heparin coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. J Card Surg 2003; 18:140-146. (Pubitemid 36470288)
6. Magnani A, Albanese A, Lamponi S, Barbucci R. Blood-interaction performance of differently sulphated hyaluronic acids. Thromb Res 1996; 81:383-395. (Pubitemid 26103283)
7. Gunaydin S, Mccusker K, Vijay V. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits. J Extra Corpor Technol 2005; 37:290-295. (Pubitemid 43160410)
8. McCarthy PM, Yared JP, Foster RC, Ogella DA, Borsh JA, Cosgrove DM. A prospective randomized trial of duraflo II heparin coated circuits in cardiac reoperations. Ann Thorac Surg 1999; 67:1268-1273. (Pubitemid 29320213)
9. Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993; 164:193-202. (Pubitemid 23285873)
10. Tanaka M,Motomura T, Kawada M, Anzai T, Kasori Y, Shiroya T, et al. Blood compatible aspects of poly(2-methoxyethylacrylate) relationship between protein adsorption and platelet adhesion on PMEA surface. Biomaterials 2000; 21:1471-1481. (Pubitemid 30259291)
11. Ulusoy A, Onur MA. Measurement of in vitro phagocytic activity using functional groups carrying monodisperse poly(glycidyl methacrylate) microspheres in rat blood. J Biomater Sci Polymer Edn 2003; 14:1299-1310. (Pubitemid 37483507)
12. Gunaydin S, Farsak B, Kocakulak M, Sari T, Yorgancioglu C, Zorlutuna Y. Clinical performance and biocompatibility of poly (2-methoxyethylacrylate) coated extracorporeal circuits. Ann Thorac Surg 2002; 74:819-824. (Pubitemid 35001813)
13. Gunaydin S. Clinical significance of coated extracorporeal circuits: a review of novel technologies. Perfusion 2004; 19:S33-S41. (Pubitemid 38607522)
14. Gunaydin S. Emerging technologies in biocompatible surface modifying additives: Quest for physiologic cardiopulmonary bypass. Curr Med Chem- Cardiovascular & Hematologic Agents 2004; 2:295-302. (Pubitemid 39200174)
15. de Vroege R, Stooker W, van Oeveren W, Bakker EW, Huybregts RA, van Klarenbosch J, et al. The impact of heparin coated circuits upon metabolism in vital organs: effect upon cerebral and renal function during and after cardiopulmonary bypass. ASAIO J 2005; 51:103-109. (Pubitemid 40165260)
16. Amrani M, Al-Ruzzeh S. Controversy of coronary artery bypass grafting with or without cardiopulmonary bypass. J Cardiovasc Med 2007; 8:89-90. (Pubitemid 46256975)
17. Palatianos GM, Foroulis CN, Vassili MI, Astras G, Triantafillou K, Papadakis E, et al. A prospective, double blind study on the efficacy of the Bioline surface heparinized extracorporeal perfusion circuit. Ann Thorac Surg 2003; 76:129-135. (Pubitemid 36819728)
18. Ovrum E, Brosstad F, Holen EA, Tangen G, Adelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin coated cardiopulmonary bypass. Circulation 1995; 92:2579-2584.
19. Andrew P, Montenero AS. Is there a link between atrial fibrillation and certain bacterial infections? J Cardiovasc Med 2007; 8:990-996.